UCI statement on Fabio Taborre and UCI Professional Continental Team Androni Giocattoli-Sidermec

The Union Cycliste Internationale (UCI) announces that it has notified Italian rider Fabio Taborre of an Adverse Analytical Finding (AAF) of FG-4592 (*) in a sample collected during an out-of-competition test on 16 June 2015.

The rider has the right to request and attend the analysis of the B sample.

In accordance with UCI Anti-doping Rules (UCI ADR), the rider has been provisionally suspended until the adjudication of the affair.

This constitutes the second AAF for a member of the UCI Professional Continental Team

Androni Giocattoli-Sidermec (**) since the beginning of 2015 and within a twelve-month period. Therefore article 7.12.1 UCI ADR providing for the suspension of the Team from 15 to 45 days (***) will be applied.

The UCI will refer the matter to the Disciplinary Commission which will render a decision in the upcoming days.

At this stage of the procedure, the UCI will not comment any further on any of these matters.

(*) FG-4592 is a prohibited substance that has the property of stimulating the endogenous production of EPO.

(**) On 30 June 2015, the UCI Professional Continental Team Androni Giocattoli-Sidermec Italian rider Davide Appollonio was notified of an AAF of EPO in a sample collected during an out-of-competition test on 14 June 2015.

What is FG-4592? Steve Tilford comments on that and what it may mean.

"There are lots of disturbing aspect to this whole thing, the ease of use, etc., but what bothers me the most is that FG-4592 is only in clinical trials and supposedly can’t be out there for the “public” to use.  I wonder how many other drugs that aren’t approved are being abused by athletes?  I’d assume a lot."